CN117642416A - 分拣蛋白活性调节剂 - Google Patents

分拣蛋白活性调节剂 Download PDF

Info

Publication number
CN117642416A
CN117642416A CN202280032903.0A CN202280032903A CN117642416A CN 117642416 A CN117642416 A CN 117642416A CN 202280032903 A CN202280032903 A CN 202280032903A CN 117642416 A CN117642416 A CN 117642416A
Authority
CN
China
Prior art keywords
propionylamino
hydroxyphenyl
alkyl
acid
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032903.0A
Other languages
English (en)
Chinese (zh)
Inventor
保罗·布莱恩·黎托
曼努埃尔·哈维尔·卡瑟斯·托马斯
麦德斯·富格桑·克约尔比
安德斯·纽易尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innocence Ltd
Original Assignee
Innocence Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innocence Ltd filed Critical Innocence Ltd
Publication of CN117642416A publication Critical patent/CN117642416A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Sawing (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Secondary Cells (AREA)
CN202280032903.0A 2021-05-14 2022-05-13 分拣蛋白活性调节剂 Pending CN117642416A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21173972.7A EP4089102A1 (en) 2021-05-14 2021-05-14 Modulators of sortilin activity
EP21173972.7 2021-05-14
PCT/EP2022/063049 WO2022238565A2 (en) 2021-05-14 2022-05-13 Compounds

Publications (1)

Publication Number Publication Date
CN117642416A true CN117642416A (zh) 2024-03-01

Family

ID=75936805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032903.0A Pending CN117642416A (zh) 2021-05-14 2022-05-13 分拣蛋白活性调节剂

Country Status (8)

Country Link
US (1) US20240294569A1 (cg-RX-API-DMAC7.html)
EP (2) EP4089102A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517498A (cg-RX-API-DMAC7.html)
KR (1) KR20240007137A (cg-RX-API-DMAC7.html)
CN (1) CN117642416A (cg-RX-API-DMAC7.html)
AU (1) AU2022275011A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217317A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022238565A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471047A1 (en) * 2023-05-31 2024-12-04 Insusense ApS Modulators of sortilin activity
EP4361165A1 (en) * 2022-10-24 2024-05-01 Insusense ApS Modulators of sortilin activity
EP4428124A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428121A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Modulators of sortilin activity
EP4428122A1 (en) * 2023-03-07 2024-09-11 Vesper Bio Aps Sortiline modulators
JP2026509275A (ja) * 2023-03-07 2026-03-17 ベスパー バイオ アーペーエス ソルチリン修飾剤
EP4719366A1 (en) 2023-05-26 2026-04-08 Bertram Wiedenmann Sortilin inhibitors for treatment of patients with functional neuroendocrine tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW217417B (cg-RX-API-DMAC7.html) * 1991-12-04 1993-12-11 Manyu Seiyaku Kk
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
US9682967B2 (en) * 2013-01-28 2017-06-20 H. Lundbeck A/S N-substituted-5-substituted phthalamic acids as sortilin inhibitors
WO2015131100A1 (en) 2014-02-28 2015-09-03 The Scripps Research Institute Ligand-controlled c(sp3)-h arylation and olefination in synthesis of unnatural chiral alpha amino acids
US20160331746A1 (en) 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake
CN110035775A (zh) * 2016-11-15 2019-07-19 学校法人东京理科大学 Ras蛋白分解诱导分子和药物组合物
CN109280075B (zh) * 2017-07-21 2022-05-20 四川海思科制药有限公司 肽酰胺类化合物及其制备方法和在医药上的用途

Also Published As

Publication number Publication date
JP2024517498A (ja) 2024-04-22
EP4089102A1 (en) 2022-11-16
WO2022238565A3 (en) 2023-02-23
CA3217317A1 (en) 2022-11-17
WO2022238565A2 (en) 2022-11-17
AU2022275011A1 (en) 2023-11-23
EP4337674A2 (en) 2024-03-20
AU2022275011A9 (en) 2023-11-30
US20240294569A1 (en) 2024-09-05
KR20240007137A (ko) 2024-01-16

Similar Documents

Publication Publication Date Title
US20240217922A1 (en) Modulators of sortilin activity
KR20240007137A (ko) 소르틸린 활성 조절제
WO2022074119A1 (en) A sortilin antagonist for use in the prevention or treatment of hearing loss
JP2024537619A (ja) 中枢神経系の疾患の処置における使用のためのソルチリンモジュレーターとしての2-アミノ-5,5-ジメチルヘキサン酸誘導体
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
JP2025508927A (ja) ソルチリン依存性疾患を治療するためのアミノ酸ベースのカルバメート及び/又は尿素
US12630558B2 (en) Pyridine derivatives as modulators of sortilin activity
EP4428121A1 (en) Modulators of sortilin activity
EP4428124A1 (en) Modulators of sortilin activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Denmark

Address after: Tanba Goro haro

Applicant after: Wisper Biological Applications Co.,Ltd.

Address before: Tanba Goro haro

Applicant before: Innocence Ltd.

Country or region before: Denmark

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: Denmark

Address after: Room 4, 10 Hauser Street, Copenhagen, Denmark

Applicant after: Wisper Biological Applications Co.,Ltd.

Address before: Tanba Goro haro

Applicant before: Wisper Biological Applications Co.,Ltd.

Country or region before: Denmark

CB02 Change of applicant information